COPD
-
Patients with COPD, bronchiectasis experience sex-based disparities in care
Radmila Choate, PhD, MPH, and her team sought to capture “lived experiences in a way that helps clinicians recognize patterns that differ for women and men and adapt care more thoughtfully.”
-
Mucus plug gene expression could identify new COPD targets
Recent research has identified distinct gene clusters that may underly the clinical heterogeneity of mucus pathology and inform further studies, investigator Ehab Billatos, MD, said.
-
CMS releases updated guidance for NIPPV in patients with COPD
Understand the new CMS guidance, which comes after more than a decade of strategic advocacy efforts led by CHEST.
-
The climate cost of inhalers: What prescribers should know
Experts said clinicians must ensure patients have the therapies they need at affordable prices that, ideally, impose minimal amounts of environmental harm.
-
Study explores geographic disparities in tobacco dependence treatment among veterans with COPD
Study author Arianne K. Baldomero, MD, said that reducing geographic barriers will require multidisciplinary approaches and innovative, equitable health care solutions.
-
Case discussions to address complexities of mediastinal lymphadenopathy diagnosis
Sebastian Kurz, MD, PhD, FCCP, will chair a Wednesday afternoon panel session that will guide attendees through imaging findings, differential diagnoses, and clinical decision-making in mediastinal lymphadenopathy.
-
Presenters to share insights into new ventilation reimbursement criteria
Peter Gay, MD, FCCP, will chair a session about the implications of revised coverage guidelines for noninvasive positive pressure ventilation devices for patients with COPD.
-
Clinicians to examine opportunities to confront dyspnea in COPD
Muhammad A. Zafar, MD, MSc, will chair a session exploring how dyspnea—more than just shortness of breath and discomfort—can be part of a downward spiral accompanying COPD.
-
Prevention of COPD exacerbations with an eosinophilic endotype
With the recent US approval of the IL-5-directed monoclonal antibody mepolizumab as an add-on therapy for patients with COPD, the era of COPD biologics is undeniably here.
-
Persistent mucus plugs linked to faster lung function decline in COPD
Investigator Sofia Mettler, MD, MPH, said the findings may point to a potential intervenable pathology in obstructive airway disease.
